Severe community-acquired pneumonia

Česká verzia

Authors: Jakubec P.
Authors place of work: Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc
Published in the journal: Kardiol Rev Int Med 2019, 21(3): 129-134

Summary

Community-acquired pneumonia is an acute infection of the pulmonary alveoli, respiratory bronchioles, and interstitium, which is acquired in a common environment (community). It is one of the most common infectious diseases worldwide. Severe community-acquired pneumonia is the most serious form of the disease and is associated with significant morbidity and mortality, especially in elderly, immunocompromised and severe comorbid patients. Initially, it is important to stratify the risk of illness and decide on an adequate place of care, preferably in an intensive care unit. The cornerstone of treatment is timely and adequate antibiotic treatment, treatment of acute respiratory failure and sepsis. The disease is accompanied by a number of complications, of which heart disease is one of the most common. Even now, the disease has a serious progression and often a poor prognosis, especially in risk groups of patients.

Keywords:

complications – diagnostics – severe community-acquired pneumonia – risk stratification

Zdroje

1. Restrepo MI, Anzueto A. Severe community--acquired pneumonia. Infect Dis Clin North Am 2009; 23(3): 503– 520. doi: 10.1016/ j.idc.2009.04.003.

2. Ananda-Rajah MR, Charles PG, Melvani S et al. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis 2008; 40(4): 293– 300. doi: 10.1080/ 00365540701663381.

3. Renaud B, Santin A, Coma E et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37(11): 2867– 2874. doi: 10.1097/ CCM.0b013e3181b02dbb.

4. Mandell LA, Wunderink RG, Anzueto A et al. IDSA/ ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2): S27– S72. doi: 10.1086/ 511159.

5. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 (Suppl 4): 1– 64. doi: 10.1136/ thorax.56.suppl_4.iv1.

6. Bauer, TT, Ewig, S, Marre R et al. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260(1): 93– 101. doi: 10.1111/ j.1365-2796.2006.01657.x.

7. Marti C, Garin N, Grosgurin O et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012; 16(4): R141. doi: 10.1186/ cc11447.

8. Li HY, Guo Q, Song WD et al. Priority for treatment and intensit care of patients with non-severe community-acquired pneumonie. Am J Med Sci 2018; 356(4): 329– 334. doi: 10.1016/ j.amjms.2018.08.002.

9. West FM, Awsare BK. Putting the CAP on ICU admissions: can clinical prediction tools help determine appropriate site of care? Am J Med Sci 2018; 356(4): 313– 314. doi: 10.1016/ j.amjms.2018.08.007.

10. Guo Q, Song WD, Li HY et al. Scored minor criteria for severe community-acquired pneumonia predicted better. Respir Res 2019; 20(1): 22. doi: 10.1186/ s12931-019-0991-4.

11. Karhu J, Ala-Kokko TI, Ohtonen P et al. Severe community-acquired pneumonia treated with beta-lactam-respiratory quinolone vs. beta-lactam-macrolide combination. Acta Anaesthesiol Scand 2013; 57(5): 587– 593. doi: 10.1111/ aas.12081.

12. Ewig S, Woodhead M, Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011; 37(2): 214– 223. doi: 10.1007/ s00134-010-2077-0.

13. Jain S, Self WH, Wunderink RG et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373(5): 415– 427. doi: 10.1056/ NEJMoa1500245.

14. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl 3): 1– 55. doi: 10.1136/ thx.2009.121434.

15. Cillóniz C, Ewig S, Ferrer M et al. Community--acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care 2011; 15(5): R209. doi: 10.1186/ cc10444.

16. Kawai S, Ochi M, Nakagawa T et al. Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan. J Infect Chemother 2004; 10(6): 352– 358. doi: 10.1007/ s10156-004-0350-2.

17. Shah BA, Singh G, Naik MA et al. Bacteriological and clinical profile of Community acquired pneumonia in hospitalized patients. Lung India 2010; 27(2): 54– 57. doi: 10.4103/ 0970-2113.63606.

18. Cillóniz C, Dominedo C, Nicolini A et al. PES pathogens in severe community-acquired pneumonia. Microorganisms 2019; 7(2): 49. doi: 10.3390/ microorganisms7020049.

19. Cillóniz C, Ewig S, Polverino E et al. Community--acquired pneumonia in outpatients: etiology and outcomes. Eur Respir J 2010; 40(4): 931– 938.

20. Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011; 43(8): 609– 615. doi: 10.3109/ 00365548.2011.570785.

21. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011; 52 (Suppl 4): 346– 350. doi: 10.1093/ cid/ cir050.

22. Ramírez P, Ferrer M, Martí V et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011; 39(10): 2211– 2217. doi: 10.1097/ CCM.0b013e3182257445.

23. Krüger S, Ewig S, Marre R. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31(2): 349– 355. doi: 10.1183/ 09031936.00054507.

24.Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections – summary. Clin Microbiol Infect 2011; 17 (Suppl 6): 1– 24. doi: 10.1111/ j.1469-0691.2011.03602.x.

25. Johansson N, Kalin M, Tiveljung-Lindell A et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50(2): 202– 209. doi: 10.1086/ 648678.

26. Shibli F, Chazan B, Nitzan O et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. Isr Med Assoc J 2010; 12(8): 477– 482.

27. Garin N, Marti C. Community-acquired pneumonia: the elusive quest for the best treatment strategy. J Thorac Dis 2016; 8(7): E571– E574. doi: 10.21037/ jtd.2016.05.13.

28. Lee JS, Giesler DL, Gellad WF et al. Antibiotic therapy for adults hospitalized with community--acquired pneumonia: a systematic review. JAMA 2016; 315(6): 593– 602. doi: 10.1001/ jama.2016.0115.

29. Dellinger RP. A lifetime of critical care: changes. Crit Care Med 2016; 44(4): 653– 654. doi: 10.1097/ CCM.0000000000001734.

30. Gattarello S, Lagunes L, Vidaur L et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. Crit Care 2015; 19: 335. doi: 10.1186/ s13054-015-1051-1.

31. Kolek V, Kolář M, Kašák V a kol. Diagnostika a léčba komunitní pneumonie dospělých. In: Kolek Vet al. Doporučené postupy v pneumologii. Praha: Maxdorf 2013: 107– 123.

32. Jakubec P, Kolek V, Kolář M. Diagnostika a léčba těžké pneumonie. In: Kolek V a kol. Doporučené postupy v pneumologii. Praha: Maxdorf 2013: 124– 140.

33. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2(5): 395– 404. doi: 10.1016/ S2213-2600(14)70041-4.

34. Frat JP, Arnaud WT, Mercat A et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372(23): 2185– 2196. doi: 10.1056/ NEJMoa1503326.

35. Ferrer M, Cosentini R, Nava S. The use of non-invasive ventilation during acute respiratory failure due to pneumonia. Eur J Inter Med 2012; 23(5): 420– 428. doi: 10.1016/ j.ejim.2012.02.011.

36. Stefan MS, Priya A, Pekow PS et al. The comparative effectiveness of nonivasive and invasive ventilation in patients with pneumonia. J Crit Care 2018; 43: 190– 196. doi: 10.1016/ j.jcrc.2017.05.023.

37. Wan YD, Sun TW, Liu ZQ et al. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 2016; 149(1): 209– 219. doi: 10.1378/ chest.15-1733.

38. Huang J, Guo J, Li H et al. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia. A systematic review and meta-analysis. Medicine 2019; 98(13): e14636. doi: 10.1097/ MD.0000000000014636.

39. Corrales-Medina VF, Musher DM, Shachkina Set al. Acute pneumonia and the cardiovascular system. Lancet 2013; 381(9865): 496– 505. doi: 10.1016/ S0140-6736(12)61266-5.

40. Viasus D, Garcia-Vidal C, Manresa F et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013; 66(1): 27– 33. doi: 10.1016/ j.jinf.2012.09.003.

41. Feldman C, Anderson R. Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia. Pneumonia 2016; 8: 11. doi: 10.1186/ s41479-016-0011-0.

42. Goncalves-Pereira J, Conceicao C, Póvoa P. Community-acquired pneumonia: identification and evaluation of nonresponders. Ther Adv Infect Dis 2013; 1(1): 5– 17. doi: 10.1177/ 2049936112469017.

43. Metersky ML, Waterer G, Nsa W et al. Predictors of in-hospital vs postdischarge mortality in pneumonia. Chest 2012; 142(2): 476– 481. doi: 10.1378/ chest.11-2393.

44. Restrepo MI, Mortensen EM, Rello J et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137(3): 552– 557. doi: 10.1378/ chest.09-1547.

45. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275(2): 134– 141.

46. Kothe H, Bauer T, Marrer R et al. Outcome of community-acquired pneumonia: influence of age, residence status, and antimicrobial treatment. Eur Respir J 2008; 32(1): 139– 146. doi: 10.1183/ 09031936.00092507.

47. Sligl WI, Eurich DT, Marrie TJ. Only severely limited, premorbid functional status is associated with short- and long-term mortality in patients with pneumonia who are critically ill: a prospective observational study. Chest 2011; 139(1): 88– 94. doi: 10.1378/ chest.10-1054.

48. Lindenauer PK, Lagu T, Shieh MS et al. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003–2009. JAMA 2012; 307(13): 1405– 1413. doi: 10.1001/ jama.2012.384.

49. Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. Med Clin North Am 2011; 95(6): 1143– 1161. doi: 10.1016/ j.mcna.2011.08.007.

50. Karhu J, Ala-Kokko TI, Ylipalosaari P et al. Hospital and long-term outcomes of ICU-treated severe community- and hospital-acquired, and ventilator-associated pneumonia patients. Acta Anaesthesiol Scand 2011; 55(10): 1254– 1260. doi: 10.1111/ j.1399-6576.2011.02535.x.

51. Carron M, Freo U, Zorzi M et al. Predictors of failure of noninvasive ventilation in patients with severe community-acquired pneumonia. J Crit Care 2010; 25(3): 540.e9– e14. doi: 10.1016/ j.jcrc.2010.02.012.

52. Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care 2008; 12 (Suppl 6): S2. doi: 10.1186/ cc7025